Durbin Letter To USPlabs Targets Latest Supplement Adulterant
This article was originally published in The Tan Sheet
Executive Summary
USPlabs is under the spotlight again as perennial supplement industry critic Sen. Dick Durbin inquires about the firm’s adverse event records and other regulatory credentials. The latest supplement controversy could bolster Durbin’s efforts to tighten supplement regulations.